Project Grant R01AI198350
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $250K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Little Rock, AR 72205, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded New York University $508,500 on April 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research investigating how myeloid cells, particularly neutrophils, regulate plasma membrane homeostasis to control decisions between functional immune programs including migration, phagocytosis, and netosis. The research, conducted as a postdoctoral project at New York University School of Medicine...
- The National Institute of Allergy and Infectious Diseases awarded the University of Arkansas for Medical Sciences $447,720 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and employ innovative in vitro and in vivo platforms for studying Acinetobacter baumannii ventilator-associated pneumonia (VAP) pathogenesis and prevention strategies. The research addresses a critical gap in VAP science: A. baumannii causes approximately 30 percent of...
- The National Institute of Allergy and Infectious Diseases awarded the University of Connecticut Health Center $523,037 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of unanchored ubiquitin chains in non-canonical inflammasome signaling. The research examines how ubiquitin regulatory X domain-containing protein 1 (UBXN1) regulates caspase-4/11-mediated inflammasome activation in response to bacterial endotoxin and...
- The National Institute of Allergy and Infectious Diseases awarded Oregon Health & Science University $149,190 on November 30, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how enterobacteria inhibit intestinal epithelial cell extrusion and activate multiple inflammasomes during infection. The funded research examines the role of the NLRP1 inflammasome in the host innate immune response to Escherichia coli and related enteropathogenic...
- The National Institute of Allergy and Infectious Diseases awarded Augusta University Research Institute, Inc. $252,716 on July 15, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate pyroptosis and necroptosis signaling pathways in response to lipopolysaccharide and bacterial infection. The research develops and characterizes a transgenic mouse model carrying a T169A substitution in receptor interacting protein kinase 1 (RIPK1) to examine the balance...
- The National Institute of Allergy and Infectious Diseases awarded New York University $742,364 on August 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate autolysin control pathways in Pseudomonas aeruginosa. The research examines how bacteria regulate cell wall-degrading enzymes (autolysins) to control their activity during cell growth and division. Pseudomonas aeruginosa serves as the model organism because it causes serious human infections...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arkansas for Medical Sciences $420,335 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on June 23, 2025, for a project period extending through May 31, 2027. The project investigates the role of lytic viral genes in the pathogenesis of oncogenic gammaherpesviruses, specifically examining whether lytic gene expression drives the development and...
- The National Institute of Allergy and Infectious Diseases awarded Boston Children's Hospital $800,557 on February 19, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how the pathogen Staphylococcus aureus manipulates inflammasome activities critical to host defense. The funded research identifies mechanisms by which diverse S. aureus strains, including toxigenic and non-toxigenic variants, activate inflammasome regulatory proteins in immune cells....
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services National Institutes of Health, awarded $577,181 to The University of Texas MD Anderson Cancer Center on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to dissect a pyroptotic mechanism driven by gasdermin A (GSDMA) activation. The research examines how GSDMA is activated in sterile inflammatory conditions and cancer, focusing on the role of the...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $736,822 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial lipases drive host immunity and physiology during infection. The research focuses on Staphylococcus aureus lipases, particularly the secreted lipase GEH, which the recipient's laboratory has shown inhibits activation of innate immune cells and blunts pro-inflammatory...